Dyne CCO sells 226 shares at $26.28 average

Dyne Therapeutics, Inc. officer Johanna Friedl-Naderer, Chief Commercial Officer, reported an automatic sale of 226 shares of common stock on 2026-08-13 at a weighted average price of $26.28 per share.

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. officer Johanna Friedl-Naderer, Chief Commercial Officer, reported an automatic sale of 226 shares of common stock on 2026-08-13 at a weighted average price of $26.28 per share. The shares were sold to satisfy tax withholding obligations arising from vesting of restricted stock units under a Rule 10b5-1 binding contract, and not as a discretionary trade. Following this transaction, she directly holds 153,982 shares, which include 119,928 unvested RSUs.

Insider Trade Summary 10b5-1

Net Seller: 226 shares

Net Sell 1 txn

Insider Friedl-Naderer Johanna

Role Chief Commercial Officer

Sold 226 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	226	$26.28	$6K

Holdings After Transaction: Common Stock — 153,982 shares (Direct)

Footnotes (3)

1. F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
3. F3. Includes 119,928 unvested RSUs.

Key Figures

Shares Sold: 226 shares Weighted Average Sale Price: $26.28 per share Shares Held After Transaction: 153,982 shares +2 more

5 metrics

Shares Sold 226 shares Common stock sold on 2026-08-13 to satisfy tax withholding

Weighted Average Sale Price $26.28 per share Weighted average price for the 226 shares sold, within $26.17–$26.39 range

Shares Held After Transaction 153,982 shares Direct ownership of Dyne Therapeutics common stock following the sale

Unvested RSUs Included 119,928 RSUs Unvested restricted stock units included in post-transaction holdings

Transaction Date 2026-08-13 Date of automatic sale to cover tax withholding

Key Terms

Rule 10b5-1, restricted stock units, weighted average price, tax withholding obligations

4 terms

Rule 10b5-1 regulatory

"constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"vesting of restricted stock units granted to the Reporting Person on February 12, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DYN executive Johanna Friedl-Naderer report?

Johanna Friedl-Naderer reported a sale of 226 Dyne Therapeutics (DYN) common shares on 2026-08-13. The sale was to cover tax withholding from vesting restricted stock units, under a pre-arranged Rule 10b5-1 binding contract.

At what price were the DYN shares sold in this Form 4 filing?

The reported price is a weighted average of $26.28 per share for the 226 shares sold. Transactions occurred in a price range between $26.17 and $26.39, as disclosed in the footnote.

How many DYN shares does Johanna Friedl-Naderer hold after this transaction?

After the transaction, Johanna Friedl-Naderer directly holds 153,982 shares of Dyne Therapeutics common stock. This reported total includes 119,928 unvested restricted stock units (RSUs) that remain subject to vesting conditions.

Was the DYN insider sale by Johanna Friedl-Naderer a discretionary trade?

No. The filing states the 226-share sale was an automatic sale to satisfy tax withholding from RSU vesting. It was executed under a binding Rule 10b5-1 contract and is described as not a discretionary trade.

What is the reason for the insider sale reported for DYN on 2026-08-13?

The sale of 226 DYN shares was to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 12, 2026. It was carried out automatically under the RSU agreement.

Does the Form 4 for DYN indicate any remaining unvested RSUs for the insider?

Yes. The filing specifies that post-transaction holdings of 153,982 shares include 119,928 unvested RSUs. These restricted stock units continue to be subject to vesting as outlined in the applicable award agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:09 PM Accepted by SEC EDGAR 08/17/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friedl-Naderer Johanna

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		S(1)		226	D	$26.28(2)	153,982(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

3. Includes 119,928 unvested RSUs.

	/s/ Dan Wilson, Attorney-in-Fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)